Fig. 4: Vaccination with H3-nanovax encapsulating IAV proteins induces robust lung-resident T cell responses. | npj Vaccines

Fig. 4: Vaccination with H3-nanovax encapsulating IAV proteins induces robust lung-resident T cell responses.

From: Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

Fig. 4

C57BL/6 mice were vaccinated with H3-nanovax encapsulating CpG + either HA/NP (Pink), NA/NP (Blue), NA/M1 (Purple), or left unvaccinated (naïve). Representative flow plots and enumeration of lung and airway resident antigen-experienced CD4 (a–g) and CD8 T cells (h–m). At 45 days post-vaccination, the total number of lung (CD11ahiCD44+) (d, j) and airway (CD11aloCD44+) (e, k) resident antigen-experienced CD4 (CD45i.vAb-CD4+CD49d+) and CD8 (CD45i.vAb-CD8α+CD44+) T cells were enumerated. TRM within the lung resident, antigen-experienced CD4 and CD8 T cells were further characterized based on expression of CD69 and CD103(CD69-CD103+ CD4): (c) (red box), (f); CD69+CD103+ CD4: (c) (blue box), (g); CD69+CD103+ CD8: (i) (red box), (l); CD69+CD103- CD8: (i) (blue box), m Error bars, mean ± s.e.m. Data representative of two (a–m; M1/NA: n = 3–4 mice/group) or three (a–m; Naïve, HA/NP, and NA/NP: n = 4–5 mice/group) independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test).

Back to article page